The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies

被引：26
作者：
de Jonge, MJA
Sparreboom, A
Verweij, J
机构：
[1] Rotterdam Canc Inst, Dept Med Oncol, NL-3075 EA Rotterdam, Netherlands
[2] Univ Rotterdam Hosp, NL-3075 EA Rotterdam, Netherlands
来源：
CANCER TREATMENT REVIEWS | 1998年 / 24卷 / 03期
关键词：
D O I：
10.1016/S0305-7372(98)90050-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：205 / 220
页数：16
相关论文
共 154 条
[81]  
MANS DRA, 1996, ANN ONCOL, V7, P9
[82]   PHASE-I AND PHARMACOLOGICAL STUDY OF IRINOTECAN AND ETOPOSIDE WITH RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR SUPPORT FOR ADVANCED LUNG-CANCER [J].
MASUDA, N ;
FUKUOKA, M ;
KUDOH, S ;
MATSUI, K ;
KUSUNOKI, Y ;
TAKADA, M ;
NAKAGAWA, K ;
HIRASHIMA, T ;
TSUKADA, H ;
YANA, T ;
YOSHIKAWA, A ;
KUBO, A ;
MATSUURA, E ;
NITTA, T ;
TAKIFUJI, N ;
TERAKAWA, K ;
NEGORO, S .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (09) :1833-1841
[83]   CPT-11 IN COMBINATION WITH CISPLATIN FOR ADVANCED NON-SMALL-CELL LUNG-CANCER [J].
MASUDA, N ;
FUKUOKA, M ;
TAKADA, M ;
KUSUNOKI, Y ;
NEGORO, S ;
MATSUI, K ;
KUDOH, S ;
TAKIFUJI, N ;
NAKAGAWA, K ;
KISHIMOTO, S .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (11) :1775-1780
[84]   PHASE-I STUDY OF IRINOTECAN AND CISPLATIN WITH GRANULOCYTE-COLONY-STIMULATING FACTOR SUPPORT FOR ADVANCED NON-SMALL-CELL LUNG-CANCER [J].
MASUDA, N ;
FUKUOKA, M ;
KUDOH, S ;
KUSUNOKI, Y ;
MATSUI, K ;
NAKAGAWA, K ;
HIRASHIMA, T ;
TAMANOI, M ;
NITTA, T ;
YANA, T ;
NEGORO, S ;
TAKIFUJI, N ;
TAKADA, M .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (01) :90-96
[85]   PHASE-I AND PHARMACOLOGICAL STUDY OF IRINOTECAN IN COMBINATION WITH CISPLATIN FOR ADVANCED LUNG-CANCER [J].
MASUDA, N ;
FUKUOKA, M ;
KUDOH, S ;
KUSUNOKI, Y ;
MATSUI, K ;
TAKIFUJI, N ;
NAKAGAWA, K ;
TAMANOI, M ;
NITTA, T ;
HIRASHIMA, T ;
NEGORO, S ;
TAKADA, M .
BRITISH JOURNAL OF CANCER, 1993, 68 (04) :777-782
[86]   CPT-11 - A NEW DERIVATIVE OF CAMPTOTHECIN FOR THE TREATMENT OF REFRACTORY OR RELAPSED SMALL-CELL LUNG-CANCER [J].
MASUDA, N ;
FUKUOKA, M ;
KUSUNOKI, Y ;
MATSUI, K ;
TAKIFUJI, N ;
KUDOH, S ;
NEGORO, S ;
NISHIOKA, M ;
NAKAGAWA, K ;
TAKADA, M .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (08) :1225-1229
[87]   INHIBITION OF CIS-DIAMMINEDICHLOROPLATINUM (II)-INDUCED DNA INTERSTRAND CROSS-LINK REMOVAL BY 7-ETHYL-10-HYDROXY-CAMPTOTHECIN IN HST-1 HUMAN SQUAMOUS-CARCINOMA CELLS [J].
MASUMOTO, N ;
NAKANO, S ;
ESAKI, T ;
FUJISHIMA, H ;
TATSUMOTO, T ;
NIHO, Y .
INTERNATIONAL JOURNAL OF CANCER, 1995, 62 (01) :70-75
[88]  
MATSUO K, 1990, CANCER RES, V50, P5819
[89]   Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: Prediction of biliary index and intestinal toxicity [J].
Mick, R ;
Gupta, E ;
Vokes, EE ;
Ratain, MJ .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (07) :2012-2019
[90]   Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel [J].
Miller, AA ;
Lilenbaum, RC ;
Lynch, TJ ;
Rosner, GL ;
Ratain, MJ ;
Green, MR ;
Schilsky, RL .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) :1964-1965
45678910111213